On its way to becoming the worlds biggest seller of generic medicines Teva Pharmaceutical Industries Ltd was known for its fierce efforts to end patent protection for brandname drugs But now the Israeli drug maker is pulling out all the stops to protect one of its own brandname drugs from such a reckoning Today the US Supreme Court   of an appeals court decision that could have paved the way for generic versions of multiplesclerosis drug Copaxone Even though its a brandname medicine at a largely generic drug maker Copaxone is one of Tevas most important products Last year Copaxone rung up  billion of the companys  billion in total revenues And analysts figure it accounts for  or more of Tevas profit More on this after the jump